In Vitro Activities of Cefpirome Against the Bacteria Isolated from the Patients in ICU, Oncology and Hematology Units.
- Author:
Yunsop CHONG
1
;
Kyungwon LEE
;
Hyuk Min LEE
Author Information
1. Department of Clinical Pathology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Cefpirome;
Nosocomial infection;
Antimicrobial susceptibility
- MeSH:
Acinetobacter baumannii;
Agar;
Bacteria*;
Ceftazidime;
Ceftriaxone;
Cephalosporins;
Cloaca;
Cross Infection;
Enterococcus;
Family Characteristics;
Hematology*;
Humans;
Intensive Care Units;
Pneumonia;
Providencia;
Pseudomonas aeruginosa;
Staphylococcus aureus;
Streptococcus pneumoniae
- From:Korean Journal of Infectious Diseases
1998;30(1):75-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Infections due to antimicrobial resistant bacteria pose serious problem in the care of the patients in intensive care units, oncology and hematology. It was to determine the prevalent species and cefpirome susceptibilities of the current isolates from these patients. METHODS: Bacteria isolated from patients in the intensive care units, oncology and hematology in a fertiary care university hospital in 1997 were analyzed for the prevalent species. Antimicrobial susceptibility of the strains, most of which were isolated in 1997, was tested by the NCCLS agar dilution method. RESULTS: The proportion of potential pathogens isolated were: Staphylococcus aureus 16.1%, Acinetobacter baumannii 13.6%, Enterobacter-Serratia-Citrobacter group 12.1%, Enterococcus spp. 11.0% and Pseudomonas aeruginosa 10.4%. The lowest resistance rates were : A.baumannii to ampicillin/sulbactam (38%), P. aeruginosa to ceftazidime (37%), Providencia spp. to ceftriaxone (7%), S. marcescens to ceftazidime and cefpirome (10%), and E. coli (3%), K. pneumoniae (10%), E. cloacae (17%) and C. freundii (7%) to cefpirome. All isolates of penicillin-resistant Streptococcus pneumoniae were susceptible to cefpirome. CONCLUSION: The in vitro test suggests that cefpirome should be more useful than the other generations of cephalosporins for the treatment of various nosocomial infections including those due to the 3rd generation cephalosporin-resistant E. cloacae, S. marcescens, C. freundii and penicillin-resistant S. pneumoniae.
